Miyake Yukio | Working Group For Reproductive Toxicology Non-clinical Evaluation Subcommitee Drug Evaluation Commit

スポンサーリンク

概要

関連著者

Okuda Yasuyuki
Working Group For Reproductive Toxicology Non-clinical Evaluation Subcommitee Drug Evaluation Commit
Hirano Fumiya
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma):research & D
Numa Toshiaki
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma):toxicology Team
Endo Y
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma):clinical Safety
Nishigaki K
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma):fuji Research La
MINESHIMA Hiroshi
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
NUMA Toshiaki
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
NISHIGAKI Keiji
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
ENDO Yoshihiko
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
OGASAWARA Hiroyuki
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
HIRANO Fumiya
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
MIYAKE Yukio
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
MATSUZAWA Toshiaki
Working Group for Reproductive Toxicology, Non-clinical Evaluation Subcommitee, Drug Evaluation Comm
Matsuzawa T
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma)
Miyake Yukio
Working Group For Reproductive Toxicology Non-clinical Evaluation Subcommitee Drug Evaluation Commit
Mineshima H
Drug Safety Res. Laboratories (kakamigahara) Eisai Co. Ltd.
Ogasawara Hiroyuki
Drug Evaluation Committee The Japan Pharmaceutical Manufacturers Association (jpma):medical Research

もっと見る

著作論文

Se2-2 How pharmaceutical companies meet the ICH guideline for reproductive toxicity studies. : Consideration from a survey carried out by JPMA(Proceedings of the 27th Annual Meeting)

スポンサーリンク